Retatrutide (LY3437943) is a novel investigational peptide featuring triple agonism at the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This multi-receptor approach represents a significant evolution in metabolic peptide research, building on the single and dual agonist precedents.
Chemical Profile
| Synonym | LY3437943 |
|---|---|
| Mechanism | GLP-1R / GIPR / GCGR triple agonist |
| Peptide Type | Modified fatty acid-acylated peptide |
| Administration | Subcutaneous (research models) |
| Appearance | Lyophilized white powder |
| Purity (Aurex) | ≥99% (HPLC) |
Triple Receptor Mechanism
The triple agonist design of Retatrutide targets three distinct hormonal pathways simultaneously. GLP-1 receptor activation enhances insulin secretion in a glucose-dependent manner and slows gastric emptying. GIP receptor activation potentiates the insulin response to meals. Glucagon receptor activation increases energy expenditure and hepatic glucose output. The synergistic interaction of all three is hypothesized to produce effects greater than any single or dual pathway approach.
Research Applications
- Energy expenditure and thermogenesis studies
- Glucose-dependent insulin secretion research
- Hepatic glucose metabolism and gluconeogenesis
- Gastric emptying rate and satiety signaling
- Adipose tissue browning and metabolic remodeling
- Comparative efficacy vs single/dual agonist models
Important Research Notes
Retatrutide is an acylated peptide with a fatty acid side chain that enables albumin binding for extended half-life. When reconstituting, allow extra time for complete dissolution — the hydrophobic acyl chain can make initial solubilization slower than non-acylated peptides. Gentle warming (not exceeding 25°C) may aid dissolution if needed.